Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.65 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.65 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1485666 | 0.89 | PIK3CD (0.57) | PIK3CAPIK3CDPIK3CG | |
| SCHEMBL1485508 | 0.89 | PIK3CA (0.76) | PIK3CAPIK3CDPIK3CG | |
| SCHEMBL11967555 | 0.83 | PIK3CA (0.72) | PIK3CAPIK3CDPIK3CG | |
| SCHEMBL12688770 | 0.82 | PIK3CA (0.65) | PIK3CAPIK3CDPIK3CG | |
| SCHEMBL1485310 | 0.82 | PIK3CA (0.64) | PIK3CAPIK3CDPIK3CG | |
| SCHEMBL1485520 | 0.82 | PIK3CA (0.62) | PIK3CAPIK3CDPIK3CG | |
| SCHEMBL12838016 | 0.81 | PIK3CA (0.78) | PIK3CAPIK3CDPIK3CG | |
| SCHEMBL12689538 | 0.81 | PIK3CA (0.72) | PIK3CAPIK3CDPIK3CG | |
| SCHEMBL1485778 | 0.81 | PIK3CA (0.56) | PIK3CAPIK3CDPIK3CG | |
| SCHEMBL1485315 | 0.79 | PIK3CA (0.69) | PIK3CAPIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343955-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-01-01 | — | — | US | claimed |
| US-20120244149-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BLAQUIERE NICOLE (US) | 2012-09-27 | — | — | US | claimed |
| US-20110076292-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | claimed |
| US-9670228-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20170081341-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-03-23 | — | — | US | disclosed |
| US-20170081341-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-03-23 | — | — | US | disclosed |
| US-9546178-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-9198918-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| EP-2845592-A1 | Benzoxazepin PI3K inhibitor compounds and methods of use | F. Hoffmann-La Roche AG (CH) | 2015-03-11 | — | — | EP | disclosed |
| US-20140288047-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-09-25 | — | — | US | disclosed |
| US-8785626-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2711368-A1 | Benzoxazepin PI3K inhibitor compounds and methods of use | F. Hoffmann-La Roche AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-20140058098-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2011036280-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140058098-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | PIK3CA 2/4885PIK3CD 7/4885PIK3CG 23/4885 |
| US-20120244149-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | PIK3CA 2/4885PIK3CD 7/4885PIK3CG 23/4885 |
| US-20140288047-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | PIK3CA 2/4885PIK3CD 7/4885PIK3CG 23/4885 |
| US-20110076292-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | PIK3CA 2/4885PIK3CD 7/4885PIK3CG 23/4885 |
| US-20170081341-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | PIK3CA 2/4885PIK3CD 7/4885PIK3CG 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.